IP Library › Granted Patent US 9,493,501
Granted Patent B2
US 9,493,501 · App. 14/353,815 · Granted Nov 15, 2016

Methyltransferase inhibitors for treating cancer

Inventors: Weihong Zheng (New York, NY); Minkui Luo (New York, NY); Glorymar del Valle Ibanez Sanchez (Corona, NY)
Assignee: Memorial Sloan-Kettering Cancer Center
C07H19/14C07D473/34C07D487/04C07H19/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,493,501
App. No.
14/353,815
Granted
Nov 15, 2016
Kind
B2
Abstract

Compounds having methyltransferase inhibitory activity are disclosed. The compounds have the structure and are useful in the treatment of cancer and similar diseases associated with inappropriate methyltransferase activity.

Claims (30)

1. A compound of formula I or II

wherein:

X 1 is N or CH;

Q is NH or 0;

A is chosen from direct bond, (C 1 -C 20 )hydrocarbon, (C 1 -C 20 )oxaalkyl and (C 1 -C 20 )azaalkyl;

R 1 is chosen from —C(═NH)NH 2 , —C(═NH)NH(C 1 -C 10 )hydrocarbon, fluoro(C 1 -C 6 )hydrocarbon, and —CH(NH 2 )COOH, with the provisos that,

(1) when A is a direct bond, R 1 cannot be H;

(2) when QR 3 is OH, R 1 cannot be fluoro(C 2 -C 6 )hydrocarbon; or

the combination R 1 A is chosen from ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, cyclic hydrocarbon groups of from 3 to 8 carbon atoms, benzyl, phenethyl, cyclohexylmethyl, adamantyl, camphoryl and naphthylethyl;

R 2 is chosen from hydrogen, —C(═NH)NH 2 , —C(═NH)NH(C 1 -C 10 )hydrocarbon and —CH(NH 2 )COOH;

R 3 is chosen from H and (C 1 -C 20 ) hydrocarbon; and

n is 1 or 2.

2. A compound according to claim 1 wherein R 3 is chosen from H, methyl and ethyl.

3. A compound according to claim 1 wherein n is 2.

4. A compound according to claim 3 wherein QR 3 is OH.

5. A compound according to claim 1 of formula Ia or IIa

wherein:

X 1 is N or CH;

A is chosen from direct bond, (C 1 -C 20 )hydrocarbon, (C 1 -C 20 )oxaalkyl and (C 1 -C 20 )azaalkyl;

R 1 is chosen from —C(═NH)NH 2 , —C(═NH)NH(C 1 -C 10 )hydrocarbon, CF 3 and —CH(NH 2 )COOH, with the proviso that, when A is a direct bond, R 1 cannot be H; or

the combination R 1 A is chosen from ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, cyclic hydrocarbon groups of from 3 to 8 carbon atoms, benzyl, phenethyl, cyclohexylmethyl, adamantyl, camphoryl and naphthylethyl;

R 2 is chosen from hydrogen, —C(═NH)NH 2 , —C(═NH)NH(C 1 -C 10 )hydrocarbon and —CH(NH 2 )COOH.

6. A compound according to claim 1 of formula I or Ia wherein R 1 -A is chosen from ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl, cyclic hydrocarbon groups of from 3 to 8 carbon atoms, benzyl and (C 3 -C 6 )oxaalkyl.

7. A compound according to claim 1 of formula I or Ia wherein R 1 -A is chosen from amino(C 1 -C 6 )alkyl, benzylamino(C 1 -C 6 )alkyl and guanidino(C 1 -C 6 )alkyl.

8. A compound according to claim 1 of formula I or Ia wherein R 1 -A is chosen from HOOC(NH 2 )CH-azaalkyl and NH 2 (NH═)C-azaalkyl.

9. A compound according to claim 1 of formula II or IIa wherein R 2 -A is chosen from hydrogen, (C 1 -C 6 )alkyl, benzyl and —C(═NH)NH 2 .

10. A compound according to claim 1 wherein X 1 is N.

11. A compound according to claim 1 wherein X 1 is CH.

12. A method for inhibiting the activity of a G9a, GLP1, SET7/9, SET8, SETD2, PRMT1, PRMT3, SUV39H2, CARM1, or SMYD2-FL methyltransferase enzyme comprising bringing said methyltransferase enzyme into contact with a compound according to claim 1 .

13. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to claim 1 .

Continuity (4)
Provisional Application 61551976 · Oct 27, 2011
Provisional Application 61552236 · Oct 27, 2011
Provisional Application 61624636 · Apr 16, 2012
Related Publication 20140303106A1 · Oct 9, 2014